Csenge Advisory Group Buys 1,778 Shares of IDEXX Laboratories, Inc. $IDXX

Csenge Advisory Group lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 387.4% during the fourth quarter, Holdings Channel reports. The fund owned 2,237 shares of the company’s stock after acquiring an additional 1,778 shares during the quarter. Csenge Advisory Group’s holdings in IDEXX Laboratories were worth $1,514,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Profund Advisors LLC raised its stake in shares of IDEXX Laboratories by 12.7% in the 4th quarter. Profund Advisors LLC now owns 7,683 shares of the company’s stock valued at $5,198,000 after acquiring an additional 867 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of IDEXX Laboratories by 35.2% in the 4th quarter. ProShare Advisors LLC now owns 147,329 shares of the company’s stock valued at $99,672,000 after acquiring an additional 38,326 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in shares of IDEXX Laboratories by 45.4% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 30,675 shares of the company’s stock valued at $20,753,000 after acquiring an additional 9,580 shares in the last quarter. Gabelli Funds LLC raised its stake in shares of IDEXX Laboratories by 44.2% in the 4th quarter. Gabelli Funds LLC now owns 685 shares of the company’s stock valued at $463,000 after acquiring an additional 210 shares in the last quarter. Finally, Sapient Capital LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $265,000. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on IDXX shares. UBS Group dropped their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. BTIG Research dropped their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $546.49 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $569.38 and its two-hundred day moving average is $644.35. The company has a market cap of $43.11 billion, a P/E ratio of 40.24, a P/E/G ratio of 3.17 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12 month low of $496.61 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 27,777 shares of company stock worth $18,235,113. 0.79% of the stock is currently owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.